Nearly a century of passion and dedication

Company Story

Nearly a century of passion and dedication

Guerbet has become one of the leading experts in medical imaging worldwide. Collectively, we offer a full range of medical solutions and services in diagnostic imaging and interventional imaging.

Read more
Ourgroup Landingpage C1 Whoweare

Who we are

A pioneer in diagnostic and interventional imaging

Guerbet is a French pharmaceutical group that has been supporting healthcare professionals specialized in diagnostic and interventional imaging since 1926. Guerbet develops and markets contrast media, delivery systems, medical devices, and related solutions adapted to their needs.

Image Scan Min

What we believe in

Generating positive results for our stakeholders

Guerbet’s employees are committed to providing healthcare professionals with contrast media, medical devices, and innovative solutions that are vital for diagnostic and interventional imaging. Driven by passion, every day, we strive to combine performance, quality, and sustainable development.

Read more

Ourgroup Landingpage C1 Historyandfuture

Our history and future

A clear vision since the very beginning

It all began with Marcel Guerbet’s discovery of the first iodinated organic contrast medium in 1901. The company was later founded in 1926 by André Guerbet. Guerbet’s innovative workforce has since left its mark on medical imaging technologies and contrast media, taking the company to the next level. Today, Guerbet sells a comprehensive range of products suitable for X-Ray and Magnetic Resonance Imaging (MRI).

Guerbet recently launched a strategic initiative to develop a new business based on digital technologies and artificial intelligence with two objectives: first, to improve the productivity of radiologists, e.g. with diagnostic assistance tools, and second, to obtain a tumor tissue characterization through imaging to better guide treatments or even eventually replace a biopsy.

Read more

Discover the latest news of Guerbet

Latest news


Guerbet shows its commitment to healthcare professionals with two ranges of consumables selected for their injection solutions

Read the press release
B1 Lipiodol

Therapeutic Goods Administration (TGA) approves both an additional indication for Guerbet’s Lipiodol® Ultra-Fluid & Vectorio® in Australia

Read the press release